Breaking News, Collaborations & Alliances

Iontas and Fair Journey Biologics Partner with Quell Therapeutics

Novel target binders from Iontas/FJB will be used to uncover functional antibodies to advance Quell’s engineered Treg cell therapy pipeline.

Author Image

By: Charlie Sternberg

Associate Editor

Iontas Limited and FairJourney Biologics S.A (FJB)., leaders in the discovery and optimization of fully human antibodies, have entered into an agreement with Quell Therapeutics Limited regarding Iontas/FJB’s proprietary libraries and technology platforms.    Quell is harnessing the suppressive capacity of Tregs to develop engineered Treg cell therapies to address several conditions of immune dysfunction. Under the terms of the agreement, Iontas/FJB will provide Quell with a diverse panel of nove...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters